Categories

About IVD

About IVDSnippets

Science Club – OncoPharm project

Science Club – OncoPharm project

Our Science Club’s regular meetings provide an opportunity for our team to review the latest developments in research. The most recent meeting focused on the OncoPharm project. Our main focus this time was acute myeloid leukemia (AML). Unfortunately, successful treatment for patients with this disease is not always guaranteed. Everything depends on a very delicate

More
About IVD

UGT1A1 Genotyping: Clinical Insight into Bilirubin Metabolism and Irinotecan Toxicity

UGT1A1 Genotyping: Clinical Insight into Bilirubin Metabolism and Irinotecan Toxicity

The UGT1A1 Promoter Polymorphism The most clinically relevant genetic variation in UGT1A1 involves the number of TA repeats in the promoter region (TATA box) of the gene: Allele TA Repeats Clinical Relevance UGT1A1*1 6TA Wild-type (normal enzyme activity) UGT1A1*28 7TA Reduced transcription and decreased enzyme activity UGT1A1*36 5TA Increased transcription (rare) UGT1A1*37 8TA Markedly reduced

More
About IVD

Genotyping of TPMT Polymorphisms: Safe and Personalized Thiopurine Therapy

Genotyping of TPMT Polymorphisms: Safe and Personalized Thiopurine Therapy

Thiopurine S-methyltransferase (TPMT) is a crucial enzyme responsible for the inactivation of thiopurine drugs through S-methylation. These drugs — including azathioprine, mercaptopurine, and thioguanine — are widely used in clinical practice, especially in hematology, oncology, gastroenterology, and transplantology. Thiopurines are prodrugs that require metabolic activation to exert their cytotoxic or immunosuppressive effects. The balance between

More
About IVD

Diagnostic priorities for 2025

Diagnostic priorities for 2025

The year 2025 confirmed the growing trend of personalized medicine, in which molecular biological diagnostics is no longer an add-on but is becoming a standard tool for clinical decision-making. Take a look at which specific items from our portfolio might be useful for you.   Thrombosis Prevention and Metabolic Pathways – HEMO line The diagnosis

More
About IVD

Key Genetic Markers Linked with Ankylosing Spondylitis

Key Genetic Markers Linked with Ankylosing Spondylitis

While HLA-B27 is by far the strongest and most well-known genetic marker linked with ankylosing spondylitis, several other genetic factors also contribute to disease susceptibility and can provide additional diagnostic or research insights. 1. HLA-B27 (primary marker) Present in ~90% of patients with AS of European ancestry. Not causative by itself — about 5–10% of

More
About IVDTesting

ApoE genetic testing – a tool to prevent side effects during Lecanemab/Leqembi® treatment

ApoE genetic testing – a tool to prevent side effects during Lecanemab/Leqembi® treatment

Lecanemab belongs to the antibody-based treatment approach as might be easily derived from its name Lecanemab where specifically the mab end cap refers to a monoclonal antibody. Lecanemab is registered commercially as Leqembi® and it has been approved by the FDA (Food and Drug Administration) in an accelerated approval pathway in January 2023 however this status changed in the summer of this year when the FDA converted the Leqembi® to traditional approval [1], [2]⁠.

More